PET/CT scans in ovarian cancer: Prognostic versus predictive utility?

Minerva Medica

Volumn 100, Issue 5, 2009, Pages 415-420

  Markman, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Computed tomography; Emission computed; Ovarian neoplasms; Tomography

Indexed keywords

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; OVARY CANCER; PREDICTIVE VALIDITY; PROGNOSIS; RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77949519329     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
2. Covens A, Carey M, Bryson P, Verma S, Fung Kee FM, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002;85:71-80.
3. Vergote I, De W, I, Tjalma W, Van GM, Decloedt J, van DP. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
4. van der Burg ME, van LM, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med.
5. Griffin T. Special Report Conference 12th IGCS Biennial Meeting. Lancet Oncol 2008;9:1129.
6. Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer 1996;78:2049-62.
7. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
8. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-8.
9. Hogdall E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008;20(1):4-8.
10. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-8.
11. Rose PG, Faulhaber P, Miraldi F, bdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17-21.
12. Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5.
13. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519-28.
14. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005;97:183-91.
15. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.
16. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103:271-6.
17. Murakami M, Miyamoto T, Iida T, Tsukada H, Watanabe M, Shida M, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16 Suppl 1:99-107.
18. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography CFDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007;105:17-22.
19. Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D, et al. Integrated PET/CT as a first-line restaging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007;34:658-66.
20. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol Oncol 2007;105:145-9.
21. Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular). AHRQ Technology Assessment Report prepared by UAEPC. Available at:http://www.cms.hhs. gov/determinationprocess/downloads/id54TA.pdf. Accessed July 8, 2009.
22. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009;112:462-8.
23. Podoloff DA Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, et al. NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types. J Nad Compr Canc Netw 2009;7(Supplement 2):S1-S23.
24. Banta HD. The diffusion of the computed tomography (CT) scanner in the United States. Int J Health Serv 1980;10:251-69.
25. Deyo RA, Diehl AK, Rosenthal M. Reducing roentgenography use. Can patient expectations be altered? Arch Intern Med 1987;147:141-5.
26. Ash LM, Modic MT, Obuchowski NA, Ross JS, Brant-Zawadzki MN, Grooff PN. Effects of diagnostic information, per se, on patient outcomes in acute radiculopathy and low back pain. AJNR Am J Neuroradiol 2008;29:1098-103.
27. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN, Jr. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med 2008;168:1541-9.
28. Podratz KC, Kinney WK. Second-look operation in ovarian cancer. Cancer 1993;71(4 Suppl):1551-8.
29. Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol 2005;99:71-9.
30. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-97.
31. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
32. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17-26.
33. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-9.
34. Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron Emission Tomography in Staging Early Lung Cancer: A Randomized Trial. Ann Intern Med 2009;151:1-8.
35. Tunis S, Whicher D. The National Oncologic PET Registry: Lessons learned for coverage with evidence development. J Am Coll Radiol 2009;6:360-5.
36. Markman M. Use of positron emission tomography scans in ovarian cancer: a diagnostic technique in search of an indication. J Clin Oncol 2005;23:7385-7.